ADAR1 Capital Management LLC Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

ADAR1 Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 463.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,002 shares of the biotechnology company’s stock after acquiring an additional 32,902 shares during the period. Sarepta Therapeutics accounts for about 1.0% of ADAR1 Capital Management LLC’s investment portfolio, making the stock its 25th largest holding. ADAR1 Capital Management LLC’s holdings in Sarepta Therapeutics were worth $4,864,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. Manchester Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. boosted its holdings in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth $36,000. Finally, Steward Partners Investment Advisory LLC boosted its position in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $54.43 on Monday. The stock has a fifty day moving average price of $96.95 and a 200-day moving average price of $113.62. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12 month low of $53.20 and a 12 month high of $173.25. The firm has a market cap of $5.28 billion, a PE ratio of 43.54 and a beta of 0.93.

Analyst Ratings Changes

SRPT has been the topic of a number of research reports. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday. Deutsche Bank Aktiengesellschaft decreased their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. HC Wainwright upgraded shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price on the stock in a research note on Wednesday, April 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $163.18.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.